EUVIMEDEUVIMED entdecken
Kohortenstudie

Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study

Ashley Kieran Clift iD, David R Huang, Nadja Auerbach, Vivian N Liu, Hans Johnson, Mohit Khera

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf170 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Ashley Kieran Clift und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Manual, Menwell Ltd, Bronze Building, Southwark, London, SE1 9HZ, United Kingdom. Hauptthemen laut MEDLINE: Testosterone, Cardiovascular Diseases, Heart Disease Risk Factors, Hypogonadism. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cross-sectional analyses demonstrate associations between lower endogenous testosterone, poorer metabolic health, and cardiovascular risk. However, the longitudinal associations between treating testosterone deficiency (TD) and key markers are unclear.

Aim

To examine 12-month trends in total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), haemoglobin A1c (HbA1c), triglycerides, and triglyceride:HDL ratios during treatment for TD.

Methods

This retrospective cohort study used mixed effects models to assess marker trajectories. Outcomes Absolute and percentage changes calculated from average marker values at 0 and 12 months (overall and sub-groups).

Results

The cohort comprised 4307 men (median age 41 years; baseline BMI 28.4 kg/m2). No significant changes were observed in LDL. The average HDL level at baseline was 1.26 mmol/L (95% CI: 1.25 to 1.26), decreasing to 1.15 (95% CI: 1.10 to 1.20) at 12 months, a relative change of -8.73% (P < 0.001). There was a 1.55 mmol/mol (95% CI: -2.74 to -0.36) average reduction in HbA1c over 12 months (relative change -4.46%, P = 0.011). The average triglyceride level was 2.25 mmol/L at baseline (95% CI: 2.20 to 2.28) and 1.79 mmol/L (95% CI: 1.55 to 2.04) at 12 months, a relative change of -20.09% (P < 0.001). Men with elevated baseline triglycerides had marked reductions, from 3.13 mmol/L at baseline to (95% CI: 3.67 to 3.79) to 2.29 mmol/L at 12 months (95% CI: 1.90 to 2.68), relative change -26.84% (P < 0.001). There was a positive relationship between baseline triglyceride:HDL elevation and relative reductions; in men with a baseline ratio > 6, values went from 8.99 at baseline (95% CI: 8.80 to 9.18) to 1.90 (95% CI: 0.19 to 3.61) at month 12, a relative change of -78.86% (P < 0.001). Clinical Implications In this non-randomized study, significant reductions in HDL, HbA1c, triglycerides, and the triglyceride:HDL ratio were observed during the course of treatment for TD. Strengths & Limitations The study used a large cohort of men and explored clinically relevant sub-groups, albeit from a single healthcare provider.

Conclusions

Interventions for TD could have potential to improve longer-term cardiometabolic health in hypogonadic men. Large, prospective, controlled studies are needed to identify the causal contributions from TD treatment strategies and lifestyle changes on biochemical marker improvements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneCardiovascular DiseasesHeart Disease Risk FactorsHypogonadismHormone Replacement TherapyHumansMaleRetrospective StudiesAdultLongitudinal StudiesGlycated HemoglobinTriglyceridesMiddle AgedBiomarkersCholesterolCholesterol, HDL

Stichwörter der Autor:innen

HbA1clipidslongitudinaltestosterone replacement therapytriglyceride:hdl ratio

Substanzen

TestosteroneGlycated HemoglobinTriglyceridesBiomarkersCholesterolCholesterol, HDL

Autor:innen und Institutionen

  • Department of Clinical Research, Manual, Menwell Ltd, Bronze Building, Southwark, London, SE1 9HZ, United Kingdom.
  • Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, W12 0HS, United Kingdom.
  • Scott Department of Urology, Baylor College of Medicine Medical Centre, 1 Baylor Plaza, Houston, TX 77030, United States.

ORCID-Profile: Ashley Kieran Clift

Zitieren

APA

Clift, A. K., Huang, D. R., Auerbach, N., Liu, V. N., Johnson, H., & Khera, M. (2025). Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf170

Vancouver

Clift AK, Huang DR, Auerbach N, Liu VN, Johnson H, Khera M. Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf170

BibTeX
@article{Clift2025,
  author = {Clift, Ashley Kieran and Huang, David R and Auerbach, Nadja and Liu, Vivian N and Johnson, Hans and Khera, Mohit},
  title = {Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf170}
}
Kostenlos starten →